Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy

Kenneth B Margulies^{1

2

3}, Benjamin L Prosser^{2

3

4}

Affiliations

¹ Department of Medicine (K.B.M.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Department of Physiology (K.B.M., B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
³ Cardiovascular Institute (K.B.M., B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ Pennsylvania Muscle Institute (B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Editorial

Kenneth B Margulies et al. Circ Heart Fail. 2021 Jan.

. 2021 Jan;14(1):e008006.

doi: 10.1161/CIRCHEARTFAILURE.120.008006. Epub 2021 Jan 12.

Kenneth B Margulies^{1

2

3}, Benjamin L Prosser^{2

3

4}

¹ Department of Medicine (K.B.M.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Department of Physiology (K.B.M., B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
³ Cardiovascular Institute (K.B.M., B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ Pennsylvania Muscle Institute (B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.

No abstract available

Keywords: Editorials; cardiomegaly; cardiomyopathy, hypertrophic; mutation; myosins.

Comment on

Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.
Schuldt M, Pei J, Harakalova M, Dorsch LM, Schlossarek S, Mokry M, Knol JC, Pham TV, Schelfhorst T, Piersma SR, Dos Remedios C, Dalinghaus M, Michels M, Asselbergs FW, Moutin MJ, Carrier L, Jimenez CR, van der Velden J, Kuster DWD. Schuldt M, et al. Circ Heart Fail. 2021 Jan;14(1):e007022. doi: 10.1161/CIRCHEARTFAILURE.120.007022. Epub 2021 Jan 12. Circ Heart Fail. 2021. PMID: 33430602 Free PMC article.

1. Levy RL, Von Glahn WC. Cardiac hypertrophy of unknown cause: a study of the clinical and pathologic features in ten adults. Am Heart J. 1944; 714–741. 10.1016/S0002-8703(44)91039-2. - DOI
1. Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007; 503–12. doi: 10.1038/ncpcardio0965. - DOI - PubMed
1. Schuldt M, Pei J, Harakalova M, Dorsch LM, Schossarek S, Mokry M, Knol JC, Pham TV, Schelfhorst T, Piersma SR, Dos Remedios C, Dalinghaus M, Michels M, Asselberas F, Moutin MJ, Carrier L, Jimenez CR, van der Velden J, Kuster D. Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy. Circ Heart Fail. 2020; XX:xxx-xxx, doi: - PMC - PubMed
1. Robison P, Caporizzo MA, Bogush AI, Shenoy VB, Margulies KB, Prosser BL. Detyrosinated microtubules sense force and bear compressive load in contracting cardiomyocytes. Science. 2016; 352:aaf0659. doi: 10.1126/science.aaf0659. - DOI - PMC - PubMed
1. Chen CY, Caporizzo MA, Bedi K, Vite A, Bogush AI, Robison P, Heffler JG, Salomon AK, Kelly NA, Babu A, Morley MP, Margulies KB, Prosser BL. Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure. Nat Med. 2018; 24:1225–1233. doi: 10.1038/s41591-018-0046-2 - DOI - PMC - PubMed